IPNews® – Mountain View Pharmaceuticals (MVP) has been granted a European Patent titled “Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency.” 

The patent aims to aid in the reduction of cases in which patients with multiple sclerosis suffer from a relapse.  It adds to MVP’s portfolio of 170 worldwide patents.  To continue reading, click: Multiple Sclerosis Patent